- Rentschler Biopharma SE is expanding its CDMO services for biopharmaceutical clients in Japan and South Korea, supported by its regional partner, Summit Pharmaceuticals International (SPI).
Rentschler Biopharma SE, a global contract development and manufacturing organisation (CDMO) for biopharmaceuticals, is expanding its focus on Japan and South Korea, highlighting its optimised solutions for biologics development and manufacturing.
Japan and South Korea are key markets for Rentschler Biopharma, which has operated in the region for many years with the support of its long-term partner, Summit Pharmaceuticals International (SPI). The collaboration provides clients with local regulatory expertise and streamlined communication to support complex biologics programmes.
“We at Rentschler Biopharma are deeply grateful for the trust placed in us by our client partners in Japan and South Korea, and we look forward to deepening these relationships as well as building new strategic partnerships through continued collaboration.”
Benedikt von Braunmühl, CEO at Rentschler Biopharma
As part of its regional engagement, the company is conducting a roadshow in Japan to present new and accelerated manufacturing capabilities. Rentschler Biopharma’s portfolio spans the full drug substance lifecycle, from cell line development and upstream and downstream processing to analytical testing, product characterisation, and regulatory affairs.
